Artelo Biosciences, Inc. (Nasdaq: ARTL) announced on March 30, 2026, the successful closing of a private placement that raised approximately $11 million. The offering involved the sale of 3,188,407 shares of common stock and warrants to purchase an additional 6,376,814 shares at a combined purchase price of $3.45 per share. The funds raised will be utilized for working capital, general corporate purposes, and the repayment of certain bridge debt. The private placement was conducted under Nasdaq rules and was facilitated by H.C. Wainwright & Co. as the exclusive placement agent. The warrants have an exercise price of $3.20 per share and are exercisable immediately, expiring five and a half years from the effective date. This financing is expected to enhance Artelo's liquidity position and support its ongoing development initiatives in the pharmaceutical sector, particularly in addressing significant unmet medical needs. The company is optimistic about its compliance with Nasdaq's listing requirements following this capital raise, as it aims to maintain stockholders' equity above the mandated threshold of $2.5 million.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.